Streptozotocin-Based Chemotherapy is Still Alive in Patients with Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival
#1009
Introduction: Chemotherapy with Streptozotocin (STZ) and 5-FU or Doxorubicin (Doc) represents a standard of care for patients with well-differentiated metastatic neuroendocrine neoplasms, especially for the pancreas (PNENs). However, data to identify predictive and prognostic markers are limited.
Aim(s): Evaluation of clinicopathological characteristics and possible predictive and prognostic markers of patients receiving this combination.
Materials and methods: We retrospectively analyzed 77 patients who were treated at the University Hospital Marburg between 1995 and 2013. The median overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier and Cox regression methods, respectively.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Krug S, Boch M, Rinke A, Müller D, König A,
Keywords: streptozotocin, NEN, 5-fluorouracil, Doc,
To read the full abstract, please log into your ENETS Member account.